Initial proof-of-concept results show INV043 to be effective against multiple cancer types
Invion Limited (ASX: IVX) (“Invion” or the “Company”) is pleased to attach the following presentation on the initial proof-of-concept testing results on INV043, the latest Active Pharmaceutical Ingredient (“API”) using the PhotosoftTM technology.
These proof-of-concept tests were undertaken in collaboration with Invion’s research partner, Hudson Institute of Medical Research (Hudson Institute), on a number of cancer types.
The key findings from the studies on INV043:
- Promising preliminary results that may have application across a range of cancers
- INV043 has ~50 times greater phototoxicity than Invion’s previous API (IVX-P03) and
~600 times greater than Talaporfin sodium (widely used photosensitiser)
- Studies showed INV043 is selectively retained in malignant but not healthy tissues.
- Furthermore, no toxicity issues were identified up to 50x the therapeutic dose
- Significant regression was observed in vivo in T-cell lymphoma, triple negative breast and pancreatic cancer models
- INV043 also displayed fluorescence characteristics under blue light, which illuminated tumour growths
“These results provide direct proof-of-principle for the use of INV043 as a cancer therapy” said Dr Andrew Stephens, Group Head of the Ovarian Cancer Biomarkers Research Group at Hudson Institute.
“These early indications are promising, and may lead to new treatment options for some of the most difficult to treat cancers.”
Invion’s Chairman and Chief Executive Officer, Thian Chew commented: “By using our latest API, these initial proof-of-concept results demonstrate the potential of PhotosoftTM technology’s applications in cancer treatment. Our next steps include performing further proof-of-concept studies looking at INV043’s effect on the immune response as well as exploring its potential to work together with other therapies.”
This announcement has been approved by the Board of Invion.
CLICK HERE to read the full ASX announcement
Hudson Institute communications
t: + 61 3 8572 2697